A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Mezigdomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Celgene Corporation
- 04 Jun 2024 Results(n=101) assessing the impact of RI on the efficacy, safety, and PK of MEZI + DEX in RRMMpresented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 30 Aug 2023 Results presented in the Dana-Farber Cancer Institute Media Release.
- 30 Aug 2023 Results published in the New England Journal of Medicine